Your browser doesn't support javascript.
loading
The need for transparency of clinical evidence for medical devices in Europe.
Fraser, Alan G; Butchart, Eric G; Szymanski, Piotr; Caiani, Enrico G; Crosby, Scott; Kearney, Peter; Van de Werf, Frans.
Afiliación
  • Fraser AG; School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK; Department of Cardiovascular Sciences, Katholieke University Leuven, Leuven, Belgium. Electronic address: fraserag@cf.ac.uk.
  • Butchart EG; Retired Consultant Cardiothoracic Surgeon, University Hospital of Wales, Cardiff, UK.
  • Szymanski P; Institute of Cardiology, Warsaw, Poland.
  • Caiani EG; Department of Biomedical Engineering and e-Health, Politecnico di Milano, Milan, Italy.
  • Crosby S; Brussels Bar, Kemmlers, Brussels, Belgium.
  • Kearney P; Department of Cardiology, Cork University Hospital, Wilton, Cork, Ireland.
  • Van de Werf F; Department of Cardiovascular Sciences, Katholieke University Leuven, Leuven, Belgium.
Lancet ; 392(10146): 521-530, 2018 08 11.
Article en En | MEDLINE | ID: mdl-30017550
ABSTRACT
To use medical devices rationally, health-care professionals must base their choices of which devices to recommend for individual patients on an objective appraisal of their safety and clinical efficacy. The evidence submitted by manufacturers when seeking approval of their high-risk devices must be publicly available, including technical performance and premarket clinical studies. Giving physicians access to this information supplements the peer-reviewed scientific literature and might be essential for comparing alternative devices within any class. Interested patients should be encouraged to review the evidence for any device that has been recommended for them. The new EU law on medical devices states that the manufacturer is to prepare a summary of the evidence for any implantable or high-risk device. Defining its content, however, has been delegated to implementing legislation, which is now being considered. From a clinical perspective, it is imperative that all evidence reviewed by notified bodies and regulatory authorities is disclosed-with the exception, if justified, only of technical specifications that are considered confidential or manufacturing details that are protected as intellectual property-and public access to this evidence must be guaranteed by EU law. From ethical and other perspectives, there are no grounds for less clinical evidence being available to health-care professionals about the medical devices that they use than is already available for new pharmaceutical products. Full transparency is needed; without it, informed decisions relating to the use of new medical devices will remain impossible.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicina Basada en la Evidencia / Equipos y Suministros Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicina Basada en la Evidencia / Equipos y Suministros Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2018 Tipo del documento: Article